Key Drivers
- Strong Liquidity
- Earnings Compression
- Rising Debt
AIAI Summary
TGTX has evolved into a BRIUMVI commercial-execution story with credible upside if share gains translate into operating leverage, but its ~$8.5B valuation leaves little room for a repeat of weak profit conversion, rising debt costs, or any slowdown in its single-product franchise.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Earnings Compression
- •Rising Debt
TGTX offers strong liquidity, high gross margins, and improving quarterly cash flow, but sharply lower earnings, rising leverage, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Resistance test
- •Support holding
TGTX is technically bullish over the last month, but a decisive break above $56.90 is needed to confirm upside while $53.00–$54.00 remains key support.
Quick rebound from $53.04 to $56.87 in three days
Sentiment & News
Key News Insights:
- •BRIUMVI Share Gains
- •Raised Revenue Outlook
- •Pipeline Catalysts
TG Therapeutics' rising BRIUMVI market share, increased revenue outlook, pipeline catalysts, and institutional buying support a bullish outlook, though buyout speculation remains unconfirmed.
The developments strengthen TGTX's commercial-growth narrative and could support continued investor interest
Similar Companies in Healthcare
Other companies in the same sector with AI ratings